OTCMKTS:VACBF Nykode Therapeutics AS (VACBF) Stock Price, News & Analysis $0.52 0.00 (0.00%) (As of 09/27/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartShort Interest Get Nykode Therapeutics AS alerts: Email Address About Nykode Therapeutics AS Stock (OTCMKTS:VACBF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Nykode Therapeutics AS alerts:Sign Up Key Stats Today's Range$0.52▼$0.5250-Day Range$0.52▼$1.5052-Week Range$0.52▼$0.95VolumeN/AAverage Volume500 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewNykode Therapeutics AS, a clinical-stage biopharmaceutical company, discovers and develops novel immunotherapies. The company develops vaccines for the treatment cancer and infectious diseases. Its lead product candidates include VB10.NEO, a cancer neoantigen vaccine, which is in phase I/IIa clinical trial for the treatment of ,melanoma, lung, bladder, renal, head, and neck cancer; VB10.16, a therapeutic vaccine, which in phase II clinical trial for the treatment of human papilloma virus 16 induced malignancies, such as cervical cancer; and VB10. COV2, a COVID-19 vaccine candidate covers new SARS-CoV-2 variants. The company has collaboration agreements with Roche, Genentech, MSD, and Nektar Therapeutics; Adaptive Biotechnologies for T cell vaccine development; and research agreement with Regeneron. Nykode Therapeutics AS was founded in 2006 and is based in Oslo, Norway.Read More… NOTICE: You have until Tuesday, November 19th (Ad)On Tuesday, November 19, 2024 smart investors will collect their share of a $1.2 billion windfall... It's part of a unique strategy which has nothing to do with risky investments like options, cryptos or forex. And while it might sound crazy...Click here for the ticker >>> Receive VACBF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nykode Therapeutics AS and its competitors with MarketBeat's FREE daily newsletter. Email Address VACBF Stock News HeadlinesNykode Therapeutics AS (5VB.DU)September 17, 2024 | finance.yahoo.comNykode Therapeutics Announces Issuance of Key Patent Covering Individualized Neoantigen Based VaccinesAugust 14, 2024 | globenewswire.comWARNING: “Buffett Indicator” flashing for first time in 50 yearsThe stock market collapsed and didn't recover for an entire decade. And what we're facing today could be even worse. That's why the actions you take in the next 90 days could be crucial for your financial future.September 29, 2024 | Behind the Markets (Ad)Nykode Therapeutics Announces Updates on its Inverse Vaccine Platform at FOCIS 2024 MeetingJune 20, 2024 | globenewswire.comNykode Therapeutics Announces mRNA-LNP Cancer Vaccine Demonstrates Superior EfficacyJune 11, 2024 | globenewswire.comNykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination with KEYTRUDA® (pembrolizumab) in Patients with HPV16-Positive High-Risk Locally Advanced Cervical CancerMay 14, 2024 | globenewswire.comNykode Therapeutics - Quarterly report Q1 2024May 14, 2024 | globenewswire.comNykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical CancerApril 19, 2024 | globenewswire.comSee More Headlines VACBF Stock Analysis - Frequently Asked Questions How have VACBF shares performed this year? Nykode Therapeutics AS's stock was trading at $1.58 at the beginning of 2024. Since then, VACBF stock has decreased by 67.1% and is now trading at $0.5191. View the best growth stocks for 2024 here. How do I buy shares of Nykode Therapeutics AS? Shares of VACBF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:VACBF CUSIPN/A CIKN/A Webnykode.com Phone47-22-95-81-93FaxN/AEmployees171Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report This page (OTCMKTS:VACBF) was last updated on 9/29/2024 by MarketBeat.com Staff From Our PartnersThe Bible Says it Clear As DayIt came to me clear-as-day thanks to the Bible… in the Parable of Talents, in the book of Matthew… This pa...Prosperity Research | SponsoredWho are Nvidia’s New Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | SponsoredThe most serious warning of my careerWith the 2024 election just weeks away, a new crisis is barrelling down on America… one that could cleave the ...Porter & Company | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredThe $15 "Insider Secret" That Could Save Your RetirementWhat if I told you there's a $15 stock that a billionaire insider just poured $47 MILLION into? That's righ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nykode Therapeutics AS Please log in to your account or sign up in order to add this asset to your watchlist. Share Nykode Therapeutics AS With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.